缺铁性贫血 中国就医指南

Iron deficiency anemia (IDA) is a common hematologic disorder characterized by insufficient iron stores to support normal red blood cell production, resulting in microcytic, hypochromic anemia. It arises when iron demand exceeds supply—either due to inadequate dietary intake, impaired gastrointestinal absorption, chronic blood loss (e.g., menorrhagia, gastrointestinal bleeding from ulcers or colorectal lesions), or increased physiological requirements (e.g., pregnancy, infancy, adolescence). Pathogenically, iron depletion progresses through three stages: first, depletion of storage iron (ferritin ↓); second, reduction in serum iron and transferrin saturation with compensatory rise in total iron-binding capacity (TIBC); and third, frank anemia with low hemoglobin, low mean corpuscular volume (MCV), and low mean corpuscular hemoglobin (MCH). Without intervention, IDA impairs oxygen delivery, mitochondrial function, and cellular energetics—particularly affecting high-demand tissues like skeletal muscle, brain, and myocardium. Epidemiologically, IDA affects over 1.2 billion people globally, making it the most prevalent nutritional deficiency worldwide. Prevalence is highest among women of childbearing age (15–25% in non-pregnant, up to 40% in pregnant women), young children (20–30% under age 5), adolescents, and older adults with comorbid gastrointestinal disease. Key risk factors include vegetarian/vegan diets low in heme iron, chronic NSAID use, celiac disease, Helicobacter pylori infection, gastric bypass surgery, heavy menstrual bleeding, frequent blood donation, and undiagnosed gastrointestinal malignancy. Beyond hematologic parameters, IDA significantly diminishes quality of life: patients commonly report profound fatigue, reduced exercise tolerance, cognitive fog, irritability, pica (craving for ice, clay, or starch), restless legs syndrome, brittle nails (koilonychia), and pallor. Untreated, it contributes to impaired work productivity, school performance deficits in children, postpartum complications, heart failure exacerbation in susceptible individuals, and increased susceptibility to infections due to compromised immune cell function. Early diagnosis—via complete blood count, ferritin (gold-standard marker, though acute-phase reactant), serum iron, TIBC, and reticulocyte hemoglobin content (Ret-He)—is critical to guide targeted therapy and uncover underlying etiology, especially occult GI bleeding in adults over 50. Management must therefore integrate iron repletion with rigorous diagnostic evaluation to address root causes, ensuring sustainable recovery and preventing recurrence.

# 缺铁性贫血治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

适用人群：轻中度缺铁性贫血（Hb 90–120 g/L）、无消化道出血或吸收障碍者。

• •口服铁剂治疗（一线）：

- 多糖铁复合物/蛋白琥珀酸铁（进口/高端）：药费 280–850元/疗程；

• •基础检查费：血常规+网织红细胞+血清铁/铁蛋白/TIBC（含采血）：180–260元；
• •随访监测（每4周）：血常规+铁蛋白复查：90–120元/次。

二、静脉铁剂治疗（微创介入）

适用人群：口服不耐受、胃肠道疾病、慢性肾病、妊娠中晚期或Hb < 90 g/L需快速纠正者。

• •蔗糖铁/羧基麦芽糖铁注射液（单次剂量≤200 mg，分3–5次）：药费 1,200–3,800元/疗程；
• •术前检查（心电图+肝肾功能+过敏试验+铁蛋白）：320–450元；
• •静脉输注护理及监护费：150–260元/次。

三、特殊复杂情况处理

适用人群：反复缺铁、不明原因慢性失血（如小肠血管畸形、隐匿性肿瘤）、遗传性铁转运障碍（如DMT1突变）。

• •胃肠镜+胶囊内镜+小肠CTE联合排查：3,200–6,500元；
• •基因检测（铁代谢相关Panel）：2,600–4,800元；
• •多学科会诊（血液科+消化内科+外科）：300元/次。

方案快速选择指南

✅ 预算有限（<1,000元）：首选国产口服铁+基础检查； ✅ 急需纠正（Hb < 80 g/L或孕晚期）：静脉铁剂+规范随访（总预算约4,500–7,000元）； ✅ 反复发作/病因未明：优先胃肠镜+铁代谢评估（预算≥8,000元）。